SESSION CANCELLED

Pharmacy Grand Rounds

Diving into the HEART of Pharmacogenomic Alphabet Soup Featuring SLCO1B1 and CYP2C19

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

The use of pharmacogenomic (PGx) testing provides medical professionals a tool to personalize treatment to best meet patient needs. While initially PGx tests were not readily available and cost-prohibitive, this is no longer the case. PGx testing in clinical decision-making is being continually evaluated as providers reach for this in search of clinical guidance. This presentation will review current limitations of select pharmacogenomics tests, review of the guidelines, and literature surrounding the clinical use of PGx testing.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Review pharmacogenomics testing results for SLCO1B1/simvastatin and CYP2C19/clopidogrel
2. Describe literature defining alternative options for intermediate metabolizers of CYP2C19 and clopidogrel
3. Indicate potential treatment options for a patient case using pharmacogenomics guideline recommendations

Session Announcement

FACULTY INFORMATION

Dylan L. Kosaski, PharmD
PGY1 Health System Pharmacy Administration Resident
Mayo Clinic Hospital - Rochester, MN

Dylan received a Doctor of Pharmacy degree from Ferris State University in Grand Rapids, MI. He is currently in the first year of his Health System Pharmacy Administration residency at Mayo Clinic – Rochester. As a part of his residency training he is also completing a Masters of Business Administration in Health Informatics through New England College. His practice interests in pharmacy operations management, cardiology, and psychiatry.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Dylan L. Kosaski, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS